• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Exelixis (EXEL)

Common Shares
Sell: $43.51|Buy: $44.00|Change: 0.53 (-1.20%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Address

1851 Harbor Bay Parkway
Alameda
CA
USA
94502

Telephone

+1 650 8378194

Website

https://www.exelixis.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Exelixis Inc Fourth Quarter Earnings Conference Call for 20262027-02-10T17:00:00
Exelixis Inc Fourth Quarter Earnings Results for 20262027-02-10T00:00:00
Exelixis Inc Annual Report for 20262027-02-10T00:00:00
Exelixis Inc Third Quarter Earnings Conference Call for 20262026-11-04T17:00:00
Exelixis Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Exelixis Inc Second Quarter Earnings Conference Call for 20262026-07-28T17:00:00
Exelixis Inc Second Quarter Earnings Results for 20262026-07-28T00:00:00
Exelixis Inc Annual General Meeting for 20262026-05-28T09:00:00
Exelixis Inc First Quarter Earnings Conference Call for 20262026-05-13T17:00:00
Exelixis Inc First Quarter Earnings Results for 20262026-05-13T00:00:00
Exelixis Inc Fourth Quarter Earnings Conference Call for 20252026-02-10T17:00:00
Exelixis Inc Fourth Quarter Earnings Result for 20252026-02-10T00:00:00
Exelixis Inc Annual Report for 20252026-02-10T00:00:00

Previous key dates

NameKey Date
Exelixis Inc Fourth Quarter Earnings Conference Call for 20252026-02-10T17:00:00
Exelixis Inc Fourth Quarter Earnings Result for 20252026-02-10T00:00:00
Exelixis Inc Annual Report for 20252026-02-10T00:00:00
J.P. Morgan 2026 Healthcare Conference2026-01-12T20:15:00
Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises2025-12-10T13:00:00
Stifel 2025 Healthcare Conference2025-11-11T08:40:00
Guggenheim 2nd Annual Healthcare Innovation Conference2025-11-10T10:30:00
Exelixis Inc Third Quarter Earnings Conference Call for 20252025-11-04T17:00:00
Exelixis Inc Third Quarter Earnings Result for 20252025-11-04T00:00:00
Bernstein’s 2nd Annual Healthcare Forum2025-09-24T08:50:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T08:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-09T08:30:00
Citi’s 2025 Biopharma Back to School Conference2025-09-03T15:15:00
2025 Wells Fargo Healthcare Conference2025-09-03T12:45:00
Exelixis Inc Second Quarter Earnings Conference Call for 20252025-07-28T17:00:00
Exelixis Inc Second Quarter Earnings Results for 20252025-07-28T00:00:00
Jefferies Global Healthcare Conference 20252025-06-04T07:35:00
William Blair 45th Annual Growth Stock Conference2025-06-03T11:00:00
Exelixis Inc Annual General Meeting for 20252025-05-28T09:00:00
TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA2025-05-27T14:30:00
BofA Securities 2025 Health Care Conference2025-05-20T10:30:00
RBC Capital Markets 2025 GlobalHealthcare Conference2025-05-20T10:30:00
RBC Capital Markets 2025 Global Healthcare Conference2025-05-14T13:40:00
Exelixis Inc First Quarter Earnings Conference Call for 20252025-05-13T17:00:00
Exelixis Inc First Quarter Earnings Result for 20252025-05-13T00:00:00
2025 Leerink Partners Global Healthcare Conference2025-03-12T10:40:00
Barclays 27th Annual Global Healthcare Conference2025-03-11T13:30:00
TD Cowen 45th Annual Health Care Conference2025-03-04T09:50:00
Citi 2025 Virtual Oncology Leadership Summit2025-02-19T14:00:00
Exelixis Inc Fourth Quarter Earnings Conference Call for 20242025-02-11T17:00:00
Exelixis Inc Fourth Quarter Earnings Result for 20242025-02-11T00:00:00
Exelixis Inc Annual Report for 20242025-02-11T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.